Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    EUR1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

    Checkit

    MCap

    GBP26m

    Last close

    GBP0.24

    ▲ 3.00 (14.29%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

AFT Pharmaceuticals (ASX: AFT)

Last close As at 15/04/2024

NZD3.10

▲ −0.13 (−4.02%)

Market capitalisation

NZD326m

AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company’s product portfolio includes prescription and over-the-counter (OTC) drugs to treat a range of conditions and a proprietary nebuliser.

AFT Pharmaceuticals is a multi-product company targeting pharmacy prescription, OTC and hospital markets. Data for Maxigesic offer it a competitive advantage in a fragmented industry.

Latest Insights

View More

Healthcare | Flash note

AFT Pharmaceuticals — Poised for international market expansion

Healthcare | Update

AFT Pharmaceuticals — US milestone triggers upside and guidance bump

Healthcare | Flash note

AFT Pharmaceuticals — US maiden voyage with Maxigesic IV launch

Healthcare | Flash note

AFT Pharmaceuticals — Another R&D asset in the bag
AFT-Pharmaceuticals_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • David Flacks

    Chairman

  • Dr Hartley Atkinson

    CEO

  • Malcolm Tubby

    Chief Financial Officer

  • Michael Weinmann

    Member of the Board of Directors

  • Nathan D. Hukill

    Member of the Board of Directors

Balance Sheet

Forecast net debt (NZ$m)

25.6

Forecast gearing ratio (%)

29

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (1.0) (16.7) (8.8)
Relative (1.8) (16.8) (6.1)
52 week high/low 3.9/2.8

Financials

AFT Pharmaceuticals is a profitable New Zealand-based specialty pharmaceutical company that sells over 150 proprietary branded and generic products through its own salesforce in New Zealand and Australia, with offices across the globe to handle its growing export business. AFT reported strong H124 results with 27.2% y-o-y top-line growth, and targets an FY24 operating profit of NZ$23–25m besides intending to declare a dividend for FY24. It launched Maxigesic IV in the US in January 2024, and continues to focus on further portfolio expansion and geographical diversification. It has recently announced new manufacturing agreements for Maxigesic Rapid and Crystaderm (ahead of their expected launches in the US and China markets, respectively), partnership expansion with Hikma (to expand in Middle East) and its entry into the UK market.

Y/E Mar Revenue (NZ$m) EBITDA (NZ$m) PBT (NZ$m) EPS (c) P/E (x) P/CF (x)
2022A 130.3 21.4 18.9 19.2 16.1 16.4
2023A 156.6 21.4 16.7 11.0 28.2 30.5
2024E 187.5 25.6 22.3 15.5 20.0 21.0
2025E 223.5 30.0 26.3 18.2 17.0 17.7

Research

Update

Healthcare

AFT Pharmaceuticals — US milestone triggers upside and guidance bump

Flash note

Healthcare

AFT Pharmaceuticals — US maiden voyage with Maxigesic IV launch

Healthcare

Flash note

AFT Pharmaceuticals — Poised for international market expansion
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free